An androgen receptor N-terminal domain antagonist for treating prostate cancer

Jae-Kyung Myung, Carmen A Banuelos, Javier Garcia Fernandez, Nasrin R Mawji, Jun Wang, Amy H Tien, Yu Chi Yang, Iran Tavakoli, Simon Haile, Kate Watt, Iain J McEwan, Stephen Plymate, Raymond J Andersen, Marianne D Sadar

Research output: Contribution to journalArticle

163 Citations (Scopus)

Abstract

Hormone therapies for advanced prostate cancer target the androgen receptor (AR) ligand-binding domain (LBD), but these ultimately fail and the disease progresses to lethal castration-resistant prostate cancer (CRPC). The mechanisms that drive CRPC are incompletely understood, but may involve constitutively active AR splice variants that lack the LBD. The AR N-terminal domain (NTD) is essential for AR activity, but targeting this domain with small-molecule inhibitors is complicated by its intrinsic disorder. Here we investigated EPI-001, a small-molecule antagonist of AR NTD that inhibits protein-protein interactions necessary for AR transcriptional activity. We found that EPI analogs covalently bound the NTD to block transcriptional activity of AR and its splice variants and reduced the growth of CRPC xenografts. These findings suggest that the development of small-molecule inhibitors that bind covalently to intrinsically disordered proteins is a promising strategy for development of specific and effective anticancer agents.
Original languageEnglish
Pages (from-to)2948-2960
Number of pages13
JournalThe Journal of Clinical Investigation
Volume123
Issue number7
Early online date3 Jun 2012
DOIs
Publication statusPublished - 1 Jul 2013

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Castration
Androgen Receptor Antagonists
Intrinsically Disordered Proteins
Protein Interaction Domains and Motifs
Ligands
Heterografts
Antineoplastic Agents
Hormones
Growth

Cite this

Myung, J-K., Banuelos, C. A., Fernandez, J. G., Mawji, N. R., Wang, J., Tien, A. H., ... Sadar, M. D. (2013). An androgen receptor N-terminal domain antagonist for treating prostate cancer. The Journal of Clinical Investigation, 123(7), 2948-2960. https://doi.org/10.1172/JCI66398

An androgen receptor N-terminal domain antagonist for treating prostate cancer. / Myung, Jae-Kyung; Banuelos, Carmen A; Fernandez, Javier Garcia; Mawji, Nasrin R; Wang, Jun; Tien, Amy H; Yang, Yu Chi; Tavakoli, Iran; Haile, Simon; Watt, Kate; McEwan, Iain J; Plymate, Stephen; Andersen, Raymond J; Sadar, Marianne D.

In: The Journal of Clinical Investigation, Vol. 123, No. 7, 01.07.2013, p. 2948-2960.

Research output: Contribution to journalArticle

Myung, J-K, Banuelos, CA, Fernandez, JG, Mawji, NR, Wang, J, Tien, AH, Yang, YC, Tavakoli, I, Haile, S, Watt, K, McEwan, IJ, Plymate, S, Andersen, RJ & Sadar, MD 2013, 'An androgen receptor N-terminal domain antagonist for treating prostate cancer', The Journal of Clinical Investigation, vol. 123, no. 7, pp. 2948-2960. https://doi.org/10.1172/JCI66398
Myung J-K, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. The Journal of Clinical Investigation. 2013 Jul 1;123(7):2948-2960. https://doi.org/10.1172/JCI66398
Myung, Jae-Kyung ; Banuelos, Carmen A ; Fernandez, Javier Garcia ; Mawji, Nasrin R ; Wang, Jun ; Tien, Amy H ; Yang, Yu Chi ; Tavakoli, Iran ; Haile, Simon ; Watt, Kate ; McEwan, Iain J ; Plymate, Stephen ; Andersen, Raymond J ; Sadar, Marianne D. / An androgen receptor N-terminal domain antagonist for treating prostate cancer. In: The Journal of Clinical Investigation. 2013 ; Vol. 123, No. 7. pp. 2948-2960.
@article{bd46a3294acb4efeb144ebb644bafd10,
title = "An androgen receptor N-terminal domain antagonist for treating prostate cancer",
abstract = "Hormone therapies for advanced prostate cancer target the androgen receptor (AR) ligand-binding domain (LBD), but these ultimately fail and the disease progresses to lethal castration-resistant prostate cancer (CRPC). The mechanisms that drive CRPC are incompletely understood, but may involve constitutively active AR splice variants that lack the LBD. The AR N-terminal domain (NTD) is essential for AR activity, but targeting this domain with small-molecule inhibitors is complicated by its intrinsic disorder. Here we investigated EPI-001, a small-molecule antagonist of AR NTD that inhibits protein-protein interactions necessary for AR transcriptional activity. We found that EPI analogs covalently bound the NTD to block transcriptional activity of AR and its splice variants and reduced the growth of CRPC xenografts. These findings suggest that the development of small-molecule inhibitors that bind covalently to intrinsically disordered proteins is a promising strategy for development of specific and effective anticancer agents.",
author = "Jae-Kyung Myung and Banuelos, {Carmen A} and Fernandez, {Javier Garcia} and Mawji, {Nasrin R} and Jun Wang and Tien, {Amy H} and Yang, {Yu Chi} and Iran Tavakoli and Simon Haile and Kate Watt and McEwan, {Iain J} and Stephen Plymate and Andersen, {Raymond J} and Sadar, {Marianne D}",
year = "2013",
month = "7",
day = "1",
doi = "10.1172/JCI66398",
language = "English",
volume = "123",
pages = "2948--2960",
journal = "The Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "7",

}

TY - JOUR

T1 - An androgen receptor N-terminal domain antagonist for treating prostate cancer

AU - Myung, Jae-Kyung

AU - Banuelos, Carmen A

AU - Fernandez, Javier Garcia

AU - Mawji, Nasrin R

AU - Wang, Jun

AU - Tien, Amy H

AU - Yang, Yu Chi

AU - Tavakoli, Iran

AU - Haile, Simon

AU - Watt, Kate

AU - McEwan, Iain J

AU - Plymate, Stephen

AU - Andersen, Raymond J

AU - Sadar, Marianne D

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Hormone therapies for advanced prostate cancer target the androgen receptor (AR) ligand-binding domain (LBD), but these ultimately fail and the disease progresses to lethal castration-resistant prostate cancer (CRPC). The mechanisms that drive CRPC are incompletely understood, but may involve constitutively active AR splice variants that lack the LBD. The AR N-terminal domain (NTD) is essential for AR activity, but targeting this domain with small-molecule inhibitors is complicated by its intrinsic disorder. Here we investigated EPI-001, a small-molecule antagonist of AR NTD that inhibits protein-protein interactions necessary for AR transcriptional activity. We found that EPI analogs covalently bound the NTD to block transcriptional activity of AR and its splice variants and reduced the growth of CRPC xenografts. These findings suggest that the development of small-molecule inhibitors that bind covalently to intrinsically disordered proteins is a promising strategy for development of specific and effective anticancer agents.

AB - Hormone therapies for advanced prostate cancer target the androgen receptor (AR) ligand-binding domain (LBD), but these ultimately fail and the disease progresses to lethal castration-resistant prostate cancer (CRPC). The mechanisms that drive CRPC are incompletely understood, but may involve constitutively active AR splice variants that lack the LBD. The AR N-terminal domain (NTD) is essential for AR activity, but targeting this domain with small-molecule inhibitors is complicated by its intrinsic disorder. Here we investigated EPI-001, a small-molecule antagonist of AR NTD that inhibits protein-protein interactions necessary for AR transcriptional activity. We found that EPI analogs covalently bound the NTD to block transcriptional activity of AR and its splice variants and reduced the growth of CRPC xenografts. These findings suggest that the development of small-molecule inhibitors that bind covalently to intrinsically disordered proteins is a promising strategy for development of specific and effective anticancer agents.

U2 - 10.1172/JCI66398

DO - 10.1172/JCI66398

M3 - Article

C2 - 23722902

VL - 123

SP - 2948

EP - 2960

JO - The Journal of Clinical Investigation

JF - The Journal of Clinical Investigation

SN - 0021-9738

IS - 7

ER -